Yaacov-Garbeli Dana
Known title: Chief Financial OfficerCIK: 0001909822
Yaacov-Garbeli Dana's purchase track record
Yaacov-Garbeli Dana has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/11/2022 | ENTX | $30K | +82.0% | +88.0% | +3.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ENTX | ▲ Buy | Grant | 58,394 | $0 | 5/7/2026 | View on chart |
| ENTX | ▲ Buy | Grant | 26,316 | $0 | 7/16/2025 | View on chart |
| ENTX | ▲ Buy | Grant | 30,151 | $0 | 4/19/2024 | View on chart |
| ENTX | ▲ Buy | Open Market | 26,580 | $14K | 11/14/2022 | View on chart |
| ENTX | ▲ Buy | Open Market | 30,000 | $16K | 11/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Entera Bio gets new coverage from Guggenheim and Cantor
Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.
Entera Bio gets new coverage from Guggenheim and Cantor. Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.